Melanotan-1 vs SNAP-8
A side-by-side research comparison of Melanotan-1 and SNAP-8 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Melanotan-1 | SNAP-8 |
|---|---|---|
| Full name | Melanotan-1 (Afamelanotide) | SNAP-8 (Acetyl Octapeptide-3) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Approved (afamelanotide) / Research compound | Research compound |
| Mechanism | Selectively activates the melanocortin-1 receptor (MC1R) on melanocytes, increasing eumelanin production and providing UV photoprotection and skin darkening. | More effectively competes with SNAP-25 for SNARE complex incorporation due to longer sequence, providing greater vesicle-membrane fusion inhibition. |
| Molecular weight | 1646.85 Da | 1,075 Da |
| Half-life | ~1 hour (peptide); implant form is sustained | 8-14 hours (topical) |
| Bioavailability | Subcutaneous injection or sustained-release implant | Moderate (topical) |
| Typical dose | ~0.5-1 mg per dose (research) | 3-10% solution |
| Frequency | Daily loading then maintenance | 2x daily |
| Route | Subcutaneous injection | Topical |
Melanotan-1 reported benefits
- Skin tanning with less sun exposure
- UV photoprotection
- Fewer side effects than Melanotan-2
- Approved form for light-sensitivity disorder
SNAP-8 reported benefits
- Superior to argireline
- Deeper wrinkle reduction
- Prevents expression lines
- Good skin penetration
Related comparisons
Research and educational reference only. Not medical advice.